

**Table 8. NEUROINFLAMMATION AND CYTOKINE-TARGETED INTERVENTIONS : Targeting Complement System**

Target	Drug	Main Indications	CT Number , Title, Study Protocol	Neurological Implications
<p><b>Complement System</b></p>	<p><b>Eculizumab</b> Anti-C5 antibody</p>	<ul style="list-style-type: none"> <li>• Paroxysmal nocturnal hemoglobinuria</li> <li>• Atypical hemolytic uremic syndrome</li> <li>• Generalized myasthenia gravis</li> <li>• Neuromyelitis optica spectrum disorder</li> </ul>	<p><b>NCT04346797</b> CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort (CORIMUNO19-ECU) <b>Interventional Phase 2</b></p>	<p>Approved for <b>neuromyelitis optica</b> (Carparini et al., 2019), and <b>myasthenia gravis</b> (Frampton, 2020). Effective in patients with a genetic demyelinating neuropathy caused by CD59 mutation (Mevorach et al., 2016). It may aggravate progressive multifocal leukoencephalopathy caused by JC polyomavirus (Gomez-Cibeira et al., 2016).</p>
			<p><b>NCT04355494</b> SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 <b>Expanded Access</b></p>	
			<p><b>NCT04288713</b> Eculizumab (Soliris) in Covid-19 Infected Patients (SOLID-C19) <b>Expanded Access</b></p>	